Mindfulness as an add-on Intervention in Treatment for Problem Gambling in Clinical Settings in Sweden
ConditionProblem Gambling
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorRegion Skane
About this trial
This study will test the effects of an add-on mindfulness intervention for patients with gambling problems, added to treatment as usual, compared to a waitlist control condition. The study will primarily aim to decrease gambling behaviour compared to the control condition which receives the intervention later, after two months, and secondarily to decrease symptoms of depressive and anxiety symptoms. In addition, patients who have undergone the mindfulness intervention will be offered participation in a qualitative interview study aiming to deepen the understanding of feasibility and challenges of a mindfulness add-on intervention against gambling problems.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Enrolled in any kind of treatment for problem gambling at a regional health care unit for problem gambling or at any municipal social service unit for problem gambling, and who provides informed consent
Disqualifiers
Inability to provide informed consent due to language difficulties or due to severe mental health problems, or because of mental health problems requiring urgent psychiatric management (such as suicidal, homicidal, delirious or psychotic behavior)
Trial design
Design model
Parallel
Treatments tested in this trial
Mindfulness
BehavioralWeekly group sessions of mindfulness, for eight weeks
Treatment groups
60 Participants
are divided into 2 treatment groupsGroup A: Intervention: treatment as usual + group mindfulnessExperimental treatment 1 intervention
Group B: Control: treatment as usual + waiting list for two monthsActive comparator 1 intervention
Trial outcomes
Primary outcomes
1
Change in past 30-day gambling (NODS 30 days)
Change in the number of criteria met according to a diagnostic tool for gambling disorder, but measuring the past 30 days at baseline and at post-treatment, and 3 and 12 months post-treatment
Time frame
Post-treatment (treatment completion) and 3 and 12 months after end of treatmentSecondary outcomes
1
Change in past-2-week depressive symptoms
Change in scores on Patient Health Questionnaire-9, a well-recognised instrument measuring past-2-week depressive symptoms
Time frame
Post-treatment (treatment completion) and 3 and 12 months after end of treatment2
Change in past-2-week anxiety symptoms
Change in scores on Generalised Anxiety Disorder-7, a well-recognised instrument measuring past-2-week anxiety symptoms
Time frame
Post-treatment (treatment completion) and 3 and 12 months after end of treatmentSponsors and contacts
Click on the lead sponsor to view all of their trials.
Region Skane
Lead sponsor
Lund University
Collaborator
Source ClinicalTrials.gov